Botulinum Toxin Type A Injection in Alleviating Postoperative Pain and Improving Quality of Life in Lower Extremity Limb Lengthening and Deformity Correction: A Pilot Study

2009 ◽  
Vol 29 (5) ◽  
pp. 427-434 ◽  
Author(s):  
Reggie C. Hamdy ◽  
Kathleen Montpetit ◽  
Ellen M. Raney ◽  
Michael D. Aiona ◽  
Ramona R. Fillman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Pilot Study ◽  
Postoperative Pain ◽  
Lower Extremity ◽  
Botulinum Toxin Type A ◽  
Deformity Correction ◽  
Limb Lengthening ◽  
Botulinum Toxin Type

Effects of botulinum toxin type a on quality of life assessed with the WHOQOL-BREF in hemifacial spasm and blepharospasm

2013 ◽  
Vol 19 (1) ◽  
pp. 12-18 ◽  
Author(s):  
Azize Esra Gürsoy ◽  
Işıl Ugurad ◽  
Gülsen Babacan-Yıldız ◽  
Mehmet Kolukısa ◽  
Arif Çelebi
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

2019 ◽  
Vol 77 (5) ◽  
pp. 346-351 ◽  
Author(s):  
Emanuel de Jesus Soares de Sousa ◽  
Gustavo Celeira de Sousa ◽  
Vitor Ferreira Baia ◽  
Danusa Neves Somensi ◽  
Marília Brasil Xavier
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Botulinum Toxin ◽  
Therapeutic Option ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Chronic Neuropathic Pain ◽  
Specific Protocol

ABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. Objective: To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication. Methods: We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60. Results: Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL. Conclusion: BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.

Effect of botulinum toxin on quality of life of patients with chronic myofascial pain

2021 ◽  
Author(s):  
Edivaldo Miotto ◽  
Karina Maria Salvatore Freitas ◽  
Aline Akemi Mori ◽  
Fabricio Pinelli Valarelli ◽  
Ricardo Cesar Gobbi de Oliveira ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Myofascial Pain ◽  
Botulinum Toxin Type A ◽  
Self Care ◽  
Botulinum Toxin Type ◽  
Health Impact ◽  
Control Group ◽  
Controlled Clinical Study

Aim: This prospective controlled clinical study aimed to evaluate the effect of botulinum toxin Type A (BTX-A) on pain control and quality of life (QoL) in patients with chronic myofascial pain. Materials & methods: Patients with chronic myofascial pain were randomly divided into two groups (n = 20): counseling and self-care and Michigan-type occlusal splint (MOS) (CG-control group) or BTX-A injection (BTX-AG). The pain was evaluated with visual analogue scale and QoL with the oral health impact profile-14 (OHIP-14) questionnaire. Results: In both groups, the pain was reduced, and QoL improved after 30 days. The results of social disability and handicap were better for patients treated with counseling and self-care and MOS. Conclusion: Minimally invasive strategies and BTX-A application improved QoL and alleviated myofascial pain.

scholarly journals Quality of life of children with cerebral palsy treated with botulinum toxin: are well-being measures appropriate?

2008 ◽  
Vol 66 (3b) ◽  
pp. 652-658 ◽  
Author(s):  
Taísa R. Simões de Assis ◽  
Edilson Forlin ◽  
Isac Bruck
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Well Being ◽  
Botulinum Toxin Type ◽  
Group I ◽  
Children With Cerebral Palsy ◽  
Previously Treated

AIM: To analyze quality of life (QOL) of children with cerebral palsy (CP) treated with botulinum toxin type A (BTXA). METHOD: Two QOL evaluation tools, translated into Portuguese, were used: Pediatric Outcomes Data Collection Instrument (PODCI) and Child's Caregiver Questionnaire (CCQ). Questionnaires were answered by caregivers on two occasions. Patients were divided into 3 groups: I - patients who had been previously treated with BTXA and who underwent a session of BTXA; II - patients who used BTXA for the first time; III - patients previously treated with BTXA but did not in this interval. RESULTS: Sixty-eight patients were evaluated. In group I (n=26) the functional ability had improvement for all types of CP (p=0.04), and tetraplegic increased interaction/communication (p=0.02). In group II (n=14) positioning improved (p=0.02). Group III (n=28) showed no change in QOL. CONCLUSIONS: PODCI and CCQ are able to capture outcome in children with CP.

Sign in / Sign up

Export Citation Format

Share Document